ResMed Inc. Reports 10% Increase in Fiscal Year 2025 Net Revenue to $5.15 Billion; Net Income Rises to $1.4 Billion with EPS of $9.51

Reuters
Aug 08
ResMed Inc. Reports 10% Increase in Fiscal Year 2025 Net Revenue to $5.15 Billion; Net Income Rises to $1.4 Billion with EPS of $9.51

ResMed Inc. has announced its financial results for the fiscal year ending June 30, 2025. The company reported a net revenue of $5,146.3 million, marking a 10% increase compared to the fiscal year 2024. Gross profit rose to $3,055.0 million, a 15% increase from $2,655.3 million in the previous year. Net income reached $1,400.7 million, up from $1,021.0 million in fiscal year 2024. Earnings per diluted share increased to $9.51 from $6.92. ResMed's business operations are segmented into Sleep and Breathing Health and Residential Care Software. The company continues to focus on developing innovative products, such as the new AirSense 11 device, which offers enhanced features like a touch screen and over-the-air update capabilities. These advancements are expected to support future growth by improving patient outcomes and creating efficiencies for healthcare providers. Total operating cash flow for fiscal year 2025 was $1,751.6 million, with cash and cash equivalents totaling $1,209.5 million as of June 30, 2025. The company also declared a quarterly dividend of $0.53 per share, resulting in a total dividend payout of $310.9 million for the year. ResMed's total assets were valued at $8.2 billion, with stockholders' equity amounting to $6.0 billion.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ResMed Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0000943819-25-000035), on August 08, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10